Oxford Bioscience Partners

Xencor

Pasadena

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

Dicerna Pharmaceuticals

Lexington

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease.